United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Johnson & Johnson’s DARZALEX FASPRO shows 95% survival at 4 years in multiple myeloma DARZALEX FASPRO shows 95% four-year PFS and deep MRD responses in NDMM, raising its profile as a foundational frontline therapy. Read the full trial analysis. byPallavi MadhirajuJune 7, 2025